1. Scrip
  2. >>Business
  3. >>Financing

Finance Watch: Big Money In Post-Data Follow-On Offerings

With Cash Limited, Others Cut Programs, Jobs

 
• By Mandy Jackson

Public Company Edition: Insmed grossed $650m, Structure raised $476m and Merus brought in $400.2m after positive clinical trial results. But while CARGO raised $110m in a private placement and Day One sold a priority review voucher for $108m, Ikena, Takeda and others cut jobs.

Finance Watch Public Company
• Source: Alamy

Insmed Incorporated, Structure Therapeutics, Inc. and Merus N.V. raised more than $1.5bn combined in recent follow-on public offerings (FOPOs), taking advantage of a spike in investor interest and their surging stock prices after announcing positive clinical trial results.

Bridgewater, NJ-based Insmed’s stock price more than doubled to $48.06 on 28 May when it reported positive results from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

Ollin Launches With $100m, Two Eye Drugs And Plans To Acquire More

 
• By Mandy Jackson

The start-up, which spent two years operating in stealth mode, has a clinical-stage anti-VEGF/Ang2 drug to rival Roche’s Vabysmo, and is on the hunt for additional ophthalmology assets.

GSK Unveils Multi-Billion US Investment As Trump Visits UK

 
• By Andrew McConaghie

The UK-headquartered company is investing heavily in the US, with CEO Emma Walmsley among business leaders greeting President Trump on his state visit to the country.

Finance Watch: LB Pharmaceuticals Launches Second-Largest Biopharma IPO Of 2025 In The US

 
• By Mandy Jackson

Public Company Edition: The neuropsychiatric disease-focused firm grossed $285m in the first IPO in the US above $100m since February. Also, Avidity raised $600m in a follow-on offering, Alnylam priced a $575m note sale and Propanc joins MEI in biopharma’s cryptocurrency ranks.

Finance Watch: Kriya, Odyssey Mega-Rounds Highlight Appetite For Late-Stage VC Investments

 
• By Mandy Jackson

Private Company Edition: Early-stage drug developers saw the biggest drop in venture capital investment in Q2, according to Biomedtracker. Also, Atlas raised a $400m fund to back prior investments, Enveda’s $150m series D round and Harvey Berger will helm Arena BioWorks.

More from Business

Ollin Launches With $100m, Two Eye Drugs And Plans To Acquire More

 
• By Mandy Jackson

The start-up, which spent two years operating in stealth mode, has a clinical-stage anti-VEGF/Ang2 drug to rival Roche’s Vabysmo, and is on the hunt for additional ophthalmology assets.

Takeda APAC Head On ‘Conscious’ Pricing, Qdenga And Reverse Digital Mentoring

 
• By Anju Ghangurde

Takeda's APAC chief talks about driving affordability and access for products like Adcetris and Qdenga, focusing on the region's diverse needs. “Watch this space” he said on the Japanese group’s Innovation Capability Centers, as they shape digital solutions to transform operations.

GSK Unveils Multi-Billion US Investment As Trump Visits UK

 
• By Andrew McConaghie

The UK-headquartered company is investing heavily in the US, with CEO Emma Walmsley among business leaders greeting President Trump on his state visit to the country.